CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.

Abstract

Renal cell carcinoma (RCC) is known to be the most commonly diagnosed kidney cancer. Clear cell RCC (ccRCC) represents approximately 85 % of diagnosed RCC cases. Targeted therapeutics, such as multi-targeted tyrosine kinase inhibitors (TKI) and mTOR inhibitors, are widely used in ccRCC therapy. However, patients treated with mTOR and TKI inhibitors easily acquire drug resistance, making the therapy less effective. Here, we demonstrated that circPTEN inhibits the expression of its parental gene PTEN by reducing methylation of the PTEN promotor and inhibits GLUT1 expression by reducing m6A methylation of GLUT1, which suppresses ccRCC progression and resistance to mTOR inhibitors.

• Authors: Yangyang Zhan, Yang Liu, Rui Yang, Qiong Chen, Fei Teng, Yueying Huang, Xin Jiang, Yueming Wang, Bin Yu, Ding Zhang, Leilei Bao, Xinli Liu, Jiwei Huang
• Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy (Drug Resist Updat) Vol. 71 Pg. 101003 (Nov 2023) ISSN: 1532-2084 [Electronic] Scotland
• PMID: 37866104 (Publication Type: Journal Article)
• Copyright: Copyright © 2023. Published by Elsevier Ltd.

Chemical References

• Glucose Transporter Type 1
• MTOR Inhibitors
• Protein Kinase Inhibitors

Topics

• Humans
• Carcinoma, Renal Cell (drug therapy, genetics, pathology)
• Glucose Transporter Type 1
• Kidney Neoplasms (drug therapy, genetics, pathology)
• MTOR Inhibitors
• Protein Kinase Inhibitors (pharmacology, therapeutic use)